Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

338 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Venetoclax Dose Escalation Rapidly Activates a BAFF/BCL-2 Survival Axis in Chronic Lymphocytic Leukemia.
Luo MX, Tan T, Trussart M, Poch A, Nguyen MT, Speed TP, Hicks DG, Bandala-Sanchez E, Peng H, Chappaz S, Slade C, Utzschneider DT, Koldej RM, Ritchie D, Strasser A, Thijssen R, Ritchie ME, Tam CSL, Lindeman GJ, Huang DCS Professor, Lew TE, Anderson MA, Roberts AW, Teh CE, Gray DHD. Luo MX, et al. Among authors: roberts aw. Blood. 2024 Oct 29:blood.2024024341. doi: 10.1182/blood.2024024341. Online ahead of print. Blood. 2024. PMID: 39471335
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Blombery P, Lew TE, Dengler MA, Thompson ER, Lin VS, Chen X, Nguyen T, Panigrahi A, Handunnetti SM, Carney DA, Westerman DA, Tam CS, Adams JM, Wei AH, Huang DCS, Seymour JF, Roberts AW, Anderson MA. Blombery P, et al. Among authors: roberts aw. Blood. 2022 Feb 24;139(8):1198-1207. doi: 10.1182/blood.2021012775. Blood. 2022. PMID: 34469514 Free PMC article. Clinical Trial.
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy.
Thijssen R, Tian L, Anderson MA, Flensburg C, Jarratt A, Garnham AL, Jabbari JS, Peng H, Lew TE, Teh CE, Gouil Q, Georgiou A, Tan T, Djajawi TM, Tam CS, Seymour JF, Blombery P, Gray DHD, Majewski IJ, Ritchie ME, Roberts AW, Huang DCS. Thijssen R, et al. Among authors: roberts aw. Blood. 2022 Nov 17;140(20):2127-2141. doi: 10.1182/blood.2022016040. Blood. 2022. PMID: 35709339 Free PMC article.
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells.
Teh CE, Peng H, Luo MX, Tan T, Trussart M, Howson LJ, Chua CC, Muttiah C, Brown F, Ritchie ME, Wei AH, Roberts AW, Bryant VL, Anderson MA, Lindeman GJ, Huang DCS, Thijssen R, Gray DHD. Teh CE, et al. Among authors: roberts aw. Blood Adv. 2023 Jun 27;7(12):2733-2745. doi: 10.1182/bloodadvances.2022008221. Blood Adv. 2023. PMID: 36521105 Free PMC article.
Targeting BCL2 for the treatment of lymphoid malignancies.
Anderson MA, Huang D, Roberts A. Anderson MA, et al. Semin Hematol. 2014 Jul;51(3):219-27. doi: 10.1053/j.seminhematol.2014.05.008. Epub 2014 May 15. Semin Hematol. 2014. PMID: 25048785 Free article. Review.
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, Yu L, Brown JR, Westerman D, Si EG, Majewski IJ, Segal D, Heitner Enschede SL, Huang DC, Davids MS, Letai A, Roberts AW. Anderson MA, et al. Among authors: roberts aw. Blood. 2016 Jun 23;127(25):3215-24. doi: 10.1182/blood-2016-01-688796. Epub 2016 Apr 11. Blood. 2016. PMID: 27069256 Free PMC article.
338 results